By trapping PARP on damaged chromatin and augmenting unresolved DNA lesions, PARP inhibitors promote the generation of micronuclei and cytoplasmic DNA in prostate cancer and instigate activation of the cGAS–STING pathway. Here, STING1 is linked to prostate carcinoma.